SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cancer Vaccine Specialist Scancell's SCIB1 Phase 1/2 Clinical Trial Reports Preliminary Evidence of Immune Response and Clinical Benefit